Background: Hypertrophic cardiomyopathy (HCM) is a genetically heterogeneous disorder and differences in the clinical manifestations can be related to the presence of different disease-causing genes. MYBPC3 mutations carriers show favorable clinical courses compared to other diseasecausing genes. Polymorphisms of angiotensin-converting enzyme insertion/deletion (ACE I/D) is associated with left ventricular (LV) hypertrophy and remodeling, and could influence the difference in clinical courses of genotyped HCM.
